Background Nintedanib targets VEGF receptors 1–3, PDGF receptors α and β, FGF
receptors 1–3, and Src and Abl kinases, which are all implicated in malignant pleural …

Purpose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess
efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant …

Introduction Pemetrexed has established efficacy, and is the backbone for chemotherapy in
patients with malignant pleural mesothelioma (MPM). An International Expanded Access …

Most patients affected by malignant pleural mesothelioma (MPM) are candidates for
chemotherapy during the course of the disease, as single modality treatment or within the …

Introduction Previously published results from a randomized phase III study of pemetrexed
plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated a …

BACKGROUND. We conducted a phase 2, multicenter, open‐label study of erlotinib plus
bevacizumab in patients with malignant pleural mesothelioma who had previously received …

The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of
malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered …

Introduction The PI3K/Akt/mammalian target of rapamycin pathway is activated in a majority
of malignant pleural mesotheliomas (MPM). We evaluated the activity of everolimus, an oral …

Background Pleural mesothelioma usually presents at an advanced, incurable stage.
Chemotherapy with platinum–pemetrexed is a standard treatment. We hypothesised that the …

Introduction Malignant pleural mesothelioma (MPM) is an aggressive malignancy that most
often presents at an advanced, incurable stage. After the failure of standard first-line …